MGMT Promoter Methylation

Molecular

81287

Real-time PCR and Bisulfite modification of tumor DNA quantify CpG methylation within the MGMT gene promoter. Methylation (or hypermethylation) of the MGMT gene promoter reduces or inactivates the normal DNA-repair function of the MGMT enzyme. As a result tumors are rendered more susceptible to radiation or alkylating agent-based therapy. Testing is particularly useful in gliomas. MGMT methylation has been reported in other tumors as well, including colorectal, lung, and lymphoma, and alkylating agents and/or radiation therapy may be considered in these cases.

• Bone marrow aspirate: 1-2 mL in EDTA tube (purple top) preferred; ACD (yellow top) acceptable
• Peripheral blood: 5-10 mL in EDTA tube (purple top) preferred; ACD (yellow top) acceptable
• Fresh Tissue: Minimum of 250 mg tissue in RPMI transport media
• Formalin-Fixed Paraffin-Embedded Tissue: 1 H&E slide cut to 4 microns and 6-8 slides cut at 8 microns of BM clot or tissue fixed with 10% NBF fixative on non-charged slides. Please circle tumor for microdissection. Alternatively, the FFPE clock of the BM clot can be sent for sectioning in our lab.

Ship specimen the same day whenever possible, with refrigerated (not frozen) cold pack.

Label all tubes with at least two unique patient identifiers. Slides require one patient identifier. Identifiers include name, DOB, specimen ID# or medical record#.

5 - 7 days

Global